Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I
DEA places 3-Methoxyphencyclidine (3-MeO-PCP) into Schedule I, making it illegal to possess, manufacture, or distribute without a DEA registration. This affects any pharmacy handling controlled substances, as they must ensure no inventory or prescriptions involve this substance.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmacies handling controlled substances, especially independent, retail chain, compounding, and long-term-care pharmacies. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately upon publication (March 23, 2026).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
3-Methoxyphencyclidine is now a Schedule I controlled substance with no accepted medical use and high abuse potential.
Who it affects
All pharmacies handling controlled substances, especially independent, retail chain, compounding, and long-term-care pharmacies.
What you must do
Review inventory and prescription records to ensure no 3-MeO-PCP is present; if found, contact DEA for disposal instructions. Update policies and training to prohibit handling of this substance.
Deadline
Immediately upon publication (March 23, 2026).
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order